| Literature DB >> 32635268 |
Pierre-Eric Campos1, Gaëtan Herbette2, Christophe Chendo2, Patricia Clerc1, Florent Tintillier1, Nicole J de Voogd3,4, Eleni-Dimitra Papanagnou5, Ioannis P Trougakos5, Moran Jerabek6, Jérôme Bignon7, Géraldine Le Goff7, Jamal Ouazzani7, Anne Gauvin-Bialecki1.
Abstract
Chemical study of the CH2Cl2-MeOH (1:1) extract from the sponge Haliclona sp. collected in Mayotte highlighted three new long-chain highly oxygenated polyacetylenes, osirisynes G-I (1-3) together with the known osirisynes A (4), B (5), and E (6). Their structures were elucidated by 1D and 2D NMR spectra and HRESIMS and MS/MS data. All compounds were evaluated on catalase and sirtuin 1 activation and on CDK7, proteasome, Fyn kinase, tyrosinase, and elastase inhibition. Five compounds (1; 3-6) inhibited proteasome kinase and two compounds (5-6) inhibited CDK7 and Fyn kinase. Osirisyne B (5) was the most active compound with IC50 on FYNB kinase, CDK7 kinase, and proteasome inhibition of 18.44 µM, 9.13 µM, and 0.26 µM, respectively.Entities:
Keywords: Haliclona sp.; enzyme inhibitors; marine sponge; oxygenated polyacetylenes
Mesh:
Substances:
Year: 2020 PMID: 32635268 PMCID: PMC7401255 DOI: 10.3390/md18070350
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–6.
Figure 2Chromatogram of the fraction worked in semipreparative HPLC with molecules associated to the peaks.
1D and 2D NMR spectroscopic data (1H 600 MHz, 13C 150 MHz, CD3OD) for osirisyne G (1) at 300 K.
| No. | δC, Type | δH, mult. ( | COSY (1H-1H) | HMBC (1H-13C) |
|---|---|---|---|---|
| 1 | 161.3, C | |||
| 2 | 79.9, C | |||
| 3 | 83.4, C | |||
| 4 | 65.0, CH | 4.60, 1H, d (4.2) | 5 | 2, 3, 5 |
| 5 | 78.5, CH | 3.43, 1H, dd (8.1, 4.3) | 4, 6 | 2, 4, 6, 7 |
| 6 | 72.7, CH | 3.61, 1H, td (8.6, 2.5) | 5, 7 | 4, 8 |
| 7 | 34.3, CH2 | 1.78, 1H, m; 1.38, 1H, m | 6, 8 | |
| 8 | 24.0, CH2 | 1.57, 2H, m | ||
| 9–16 | 30.8, CH2 | 1.40–1.30, 16H, m | ||
| 17 | 24.8, CH2 | 1.54, 2H, m | 18 | |
| 18 | 43.4, CH2 | 2.46, 2H, t (7.4) | 17 | 16, 17, 19 |
| 19 | 214.5, C | |||
| 20 | 43.5, CH2 | 2.44, 2H, t (8.1) | 21 | 19, 21, 22 |
| 21 | 24.8, CH2 | 1.54, 2H, m | 20 | 19, 20, 22, 23 |
| 22 | 30.2, CH2 | 1.40, 2H, m | 21 | 21, 23, 24 |
| 23 | 30.2, CH2 | 1.48, 1H, m; 1.38, 1H, m | 24 | 21, 22, 24, 25 |
| 24 | 33.1, CH2 | 2.05, 2H, q (7.1) | 23, 25 | 22, 23, 25, 26 |
| 25 | 132.3, CH | 5.62, 1H, dtd (15.3, 6.5, 0.8) | 24, 26 | 23, 24, 26, 27 |
| 26 | 134.3, CH | 5.43, 1H, ddt (15.3, 7.1, 1.4) | 25, 27 | 24, 27 |
| 27 | 73.5, CH | 3.97, 1H, m | 26, 28 | 25, 26, 28, 29 |
| 28 | 38.1, CH2 | 1.56, 1H, m, 1.49, 1H, m | 27 | 27 |
| 29 | 22.4, CH2 | 1.50, 2H, m | 27, 31 | |
| 30 | 38.5, CH2 | 1.67, 2H, m | 31 | 31, 32 |
| 31 | 62.5, CH | 4.33, 1H, td (6.7, 1.6) | 30, 34 | 29, 30, 32, 33 |
| 32 | 85.0, C | |||
| 33 | 83.8, C | |||
| 34 | 52.3, CH | 5.11, 1H, m | 31, 37 | 32, 33, 35, 36 |
| 35 | 80.9, C | |||
| 36 | 81.9, C | |||
| 37 | 28.0, CH2 | 2.38, 2H, dd (5.9, 1.9) | 34, 38 | 35, 36, 38, 39 |
| 38 | 70.7, CH | 3.69, 1H, tt (10.9, 6.3) | 37, 39 | 36, 37, 39, 40 |
| 39 | 37.0, CH2 | 1.50, 2H, m | 38 | 37, 38 |
| 1.64, 2H, m | ||||
| 40 | 22.6, CH2 | 1.49, 2H, m | 38, 42 | |
| 41 | 38.1 CH2 | 1.58, 1H, m; 1.50, 1H, m | 42 | 42, 43 |
| 42 | 72.2, CH | 4.09, 1H, q (6.0) | 41, 43 | 40, 41, 43 |
| 43 | 136.0 CH | 5.88, 1H, ddd (15.4, 6.2, 1.3) | 42, 44 | |
| 44 | 130.3, CH | 5.76, 1H, ddd (15.4, 5.7, 1.1) | 43, 45 | 42, 43, 45, 46 |
| 45 | 62.5, CH | 4.82, 1H, dm (5.7) | 44, 47 | 43, 44, 46, 47 |
| 46 | 84.7 C | |||
| 47 | 74.9, CH | 2.92, 1H, d (2.2) | 45 | 45 |
Figure 3Partial structures of osirisynes G-I (1–3) with key 1H–1H COSY and 1H–13C HMBC correlations.
Figure 4ESI+–MS/MS (a) and ESI−–MS/MS (b) spectra of osirisyne G (1) with outlines of dissociation of the precursor ions.
Figure 5Dissociation mechanisms of the fragmentation of osirisyne G (1) in ESI+–MS/MS (a) and ESI−–MS/MS (b) with the mass m/z of the different fragments.
1D NMR spectroscopic data (1H 600MHz, 13C 150 MHz, CD3OD) for osirisynes H (2) and I (3) at 300 K.
| No. | Osirisyne H (2) | Osirisyne I (3) | ||
|---|---|---|---|---|
| δC, Type | δH, mult. ( | δC, Type | δH, mult. ( | |
| 1 | 158.6, C | 161.5, C | ||
| 2 | 80.0, C | 80.7, C | ||
| 3 | 83.3, C | 83.3, C | ||
| 4 | 65.0, CH | 4.60, 1H, d (4.3) | 67.2, CH | 4.19, 1H, d (5.2) |
| 5 | 78.5, CH | 3.43, 1H, dd (8.1, 4.3) | 75.5, CH | 3.56, 1H, ddd (8.6, 5.0, 3.4) |
| 6 | 72.9, CH | 3.62, 1H, td (8.8, 2.3) | 33.3, CH2 | 1.67, 1H, m; 1.47, 1H, m |
| 7 | 34.1, CH2 | 1.77, 1H, m; 1.38, 1H, m | 26.9, CH2 | 1.54, 1H, m; 1.35, 1H, m |
| 8 | 24.7, CH2 | 1.56, 2H, m | 30.8, CH2 | 1.40–1.30, 2H, m |
| 9–16 | 30.8, CH2 | 1.40–1.30, 16H, m | 30.8, CH2 | 1.40–1.30, 16H, m |
| 17 | 24.3, CH2 | 1.54, 2H, m | 30.5, CH2 | 1.39, 2H, m |
| 18 | 43.3, CH2 | 2.45, 2H, t (7,4) | 33.3, CH2 | 2.05, 2H, m |
| 19 | 214.5, C | 132.5, CH | 5.62, 1H, dq (14.5, 7.0) | |
| 20 | 43.3, CH2 | 2.45, 2H, t (7.4) | 134.5, CH | 5.43, 1H, ddt (15.3, 7.1, 1.3) |
| 21 | 24.3, CH2 | 1.54, 2H, m | 73.6, CH | 3.97, 1H, q (6.3) |
| 22 | 30.1, CH2 | 1.41, 2H, m | 37.9, CH2 | 1.56, 1H, m; 1.45, 1H, m |
| 23 | 30.1, CH2 | 1.40, 2H, m | 26.3, CH2 | 1.39, 2H, m |
| 24 | 33.0, CH2 | 2.05, 2H, q (7.1) | 33.2, CH2 | 2.05, 2H, m |
| 25 | 132.2, CH | 5.61, 1H, dtd (15.3, 6.7, 0.6) | 132.3, CH | 5.62, 1H, dq (14.5, 7.0) |
| 26 | 134.3, CH | 5.42, 1H, ddt (15.3, 7.1, 1.3) | 134.4, CH | 5.43, 1H, ddt (15.3, 7.1, 1.3) |
| 27 | 73.4, CH | 3.97, 1H, q (6.3) | 73.6, CH | 3.98, 1H, q (6.3) |
| 28 | 37.5, CH2 | 1.51, 2H, m | 38.1, CH2 | 1.50, 2H, m |
| 29 | 26.2, CH2 | 1.43, 2H, m | 22.5, CH2 | 1.47, 2H, m |
| 30 | 29.2, CH2 | 1.52, 2H, m | 38.8, CH2 | 1.68, 2H, m |
| 31 | 19.1, CH2 | 2.23, 2H, td (6.9, 2.0) | 62.6, CH | 4.33, 1H, td (6.7, 1.6) |
| 32 | 79.3, C | 85.5, C | ||
| 33 | 84.3, C | 84.4, C | ||
| 34 | 52.4, CH | 5.04, 1H, quint (1.8) | 52.5, CH | 5.11, 1H, q (1.7) |
| 35 | 81.1, C | 80.7, C | ||
| 36 | 81.5, C | 82.1, C | ||
| 37 | 28.0, CH2 | 2.38, 2H, dq (5.8, 1.0) | 28.1, CH2 | 2.38, 2H, dd (5.9, 2.0) |
| 38 | 70.6, CH | 3.69, 1H, m | 70.9, CH | 3.69, 1H, m |
| 39 | 36.6, CH2 | 1.50, 1H, m; 1.65, 1H, m | 37.0, CH2 | 1.50, 1H, m; 1.64, 1H, m |
| 40 | 22.3, CH2 | 1.49, 2H, m | 22.5, CH2 | 1.49, 2H, m |
| 41 | 37.8 CH2 | 1.58, 1H, m; 1.50, 1H, m | 38.1 CH2 | 1.60, 1H, m; 1.51, 1H, m |
| 42 | 72.2, CH | 4.09, 1H, q (6.1) | 72.4, CH | 4.09, 1H, q (6.1) |
| 43 | 136.0 CH | 5.88, 1H, ddd (15.4, 6.2, 1.3) | 136.2 CH | 5.88, 1H, ddd (15.3, 6.2, 1.2) |
| 44 | 130.4, CH | 5.76, 1H, ddd (15.4, 5.7, 1.1) | 130.5, CH | 5.76, 1H, ddd (15.4, 5.7, 1.1) |
| 45 | 62.4, CH | 4.82, 1H, dm (5.7) | 62.6, CH | 4.82, 1H, dm (5.7) |
| 46 | 84.0 C | 84.4 C | ||
| 47 | 74.5, CH | 2.92, 1H, d (2.2) | 74.9, CH | 2.91, 1H, d (2.2) |
Figure 6The CH2Cl2-MeOH extract of the lyophilized sponge Haliclona sp. exerted anti-melanogenic properties. Bars, ±SD; n ≥ 2.
IC50 (µM) of the 6 compounds (1–6) on CDK7, proteasome, and Fyn kinase inhibition.
| Compound | FynB Kinase Inhibition | CDK7 Kinase Inhibition | Proteasome Inhibition |
|---|---|---|---|
| Osirisyne G ( | >40.20 | >40.20 | |
| Osirisyne H ( | >40.99 | ||
| Osirisyne I ( | >40.99 | >40.99 | |
| Osirisyne A ( | >40.99 | >40.99 | |
| Osirisyne B ( | 18.44 | 9.13 | 0.26 |
| Osirisyne E ( | >41.81 | >41.81 | >41.81 |
| Staurosporine | 0.137 | 0.172 | |
| ONX-0914 | 4.63 × 10−5 |
ADP-Glo Kinase Assay (Promega) [44].
| protein | 300 nM CDK7 (Crelux construct CZY-3, PC09891) |
| substrate | 30 μM CDKtide |
| ATP | 125 μM Ultra Pure ATP (Sigma) |
| buffer | 20 mM Hepes pH 7.5, 150 mM NaCl, 10 mM MgCl2 |
| extracts | stock conc. 10 mg/mL in DMSO |
| instrument | TECAN INFINITE M1000 PRO |
| settings | Mode: Luminescence; Integration time: 100 ms |
| Compound plates | 1 mg/mL in DMSO |
Fluorescence Intensity Assay.
| Protein | Yeast proteasome (TUM Groll group) |
| Storage buffer | 20 mM Tris/HCl pH 7.5 |
| substrate | Suc-Leu-Leu-Val-Tyr-AMC (Enzo Lifesciences, BML-P802-0005) |
| assay buffer | 100 mM Tris pH 7.5, 1 mM MgCl2 |
| instrument | TECAN INFINITE M1000 PRO |
| settings | mode: Fluorescence Intensity; ex 380 nm, em 460 nm; bandwidth: +/−10 nm |
| Compound plates | 1 mg/mL in DMSO |
ADP-Glo Kinase Assay (Promega) [44].
| protein | 200 nM FynB wt (Crelux construct CTX4, PC09815-1) |
| substrate | 10 μM Fyn substrate (Enzo, P-215) |
| ATP | 100 μM Ultra Pure ATP (Promega) |
| buffer | 20 mM Tris pH 8.0, 170 mM NaCl, 10 mM MgCl2 |
| instrument | TECAN INFINITE M1000 PRO |
| settings | Mode: Luminescence; Integration time: 100 ms |
| Compound plates | 1 mg/mL in DMSO |